Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec;26(1):2532224.
doi: 10.1080/15384047.2025.2532224. Epub 2025 Jul 15.

Copper death combination therapy: the innovative frontier and challenges in prostate cancer treatment

Jia Wei He  1 , Pei Zhen Li  2 , Zi Xuan Huang  1
Affiliations
Review

Copper death combination therapy: the innovative frontier and challenges in prostate cancer treatment

Jia Wei He et al. Cancer Biol Ther. 2025 Dec.

Abstract

Prostate cancer (PCA) remains a significant health challenge, necessitating the exploration of novel therapeutic strategies to enhance patient outcomes. Recent research has identified cuproptosis, a copper-dependent programmed cell death mechanism, as a promising target in PCA treatment. Elevated copper levels have been associated with tumor progression and therapeutic resistance, highlighting the need for innovative approaches. This review synthesizes current findings on the role of copper and cuproptosis in PCA, focusing on the mechanisms underlying cuproptosis, the identification of key biomarkers, and the therapeutic potential of copper complexes and ionophores. The integration of cuproptosis-related biomarkers into clinical practice may facilitate personalized treatment strategies, while ongoing research into copper-based therapies holds promise for overcoming limitations of traditional chemotherapy. Future directions should emphasize elucidating the molecular mechanisms of cuproptosis and optimizing therapeutic applications to improve patient outcomes in PCA.

Keywords: Prostate cancer; androgen receptor; copper metabolism; drug resistance; therapeutic strategies.

PubMed Disclaimer

Conflict of interest statement

The author hereby declares that there are no financial interests, personal relationships, or any other factors that could potentially undermine the objectivity and integrity of the research presented in this document.

Figures

Figure 1.
Figure 1.
Schematic diagram of the molecular mechanism of cuproptosis in prostate cancer cells.
Figure 2.
Figure 2.
Key genes and biomarkers associated with cuproptosis in prostate cancer.
Figure 3.
Figure 3.
The interaction between cuproptosis and the immune microenvironment of prostate cancer.
See this image and copyright information in PMC

References

    1. Doğan A, Demirci S, Türkmen NB, Çağlayan AB, Aydın S, Telci D, Kılıç E, Şahin K, Orhan C, Tuzcu M, et al. Schiff base-poloxamer P85 combination prevents prostate cancer progression in C57/Bl6 mice. Prostate. 2016;76(15):1454–15. doi: 10.1002/pros.23229. - DOI - PubMed
    1. Wu J, He J, Liu Z, Zhu X, Li Z, Chen A, Lu J.. Cuproptosis: mechanism, role, and advances in urological malignancies. Med Res Rev. 2024;44(4):1662–1682. doi: 10.1002/med.22025. - DOI - PubMed
    1. Cheng B, Tang C, Xie J, Zhou Q, Luo T, Wang Q, Huang H. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis. Life Sci. 2023;325:121659. doi: 10.1016/j.lfs.2023.121659. - DOI - PubMed
    1. Milacic V, Jiao P, Zhang B, Yan B, & Dou QP. Novel 8-hydroxylquinoline analogs induce copper-dependent proteasome inhibition and cell death in human breast cancer cells. Int J Oncol. 2009;35(6):1481–1491. doi: 10.3892/ijo_00000467. - DOI - PMC - PubMed
    1. Lubiński J, Lener MR, Marciniak W, Pietrzak S, Derkacz R, Cybulski C, Gronwald J, Dębniak T, Jakubowska A, Huzarski T, et al. Serum essential elements and survival after cancer diagnosis. Nutrients. 2023;15(11):2611. doi: 10.3390/nu15112611. - DOI - PMC - PubMed

LinkOut - more resources